Antonio Bertolotto

List of Publications by Citations

251 papers	10,598 citations	53 h-index	95 g-index
262 ext. papers	11,835 ext. citations	5.3 avg, IF	5.6 L-index

#	Paper	IF	Citations
251	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *New England Journal of Medicine*, **2010**, 362, 402-15	59.2	1686
250	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2009**, 374, 1503-11	40	475
249	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet, The*, **2008**, 371, 2085-92	40	236
248	Recommendations to standardize preanalytical confounding factors in Alzheimer and Parkinson disease cerebrospinal fluid biomarkers: an update. *Biomarkers in Medicine*, **2012**, 6, 419-30	2.3	230
247	The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. *Neurology*, **2004**, 63, 919-21	6.5	221
246	Cognitive and psychosocial features of childhood and juvenile MS. *Neurology*, **2008**, 70, 1891-7	6.5	209
245	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. *Annals of Neurology*, **2021**, 89, 780-789	9.4	189
244	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. *Multiple Sclerosis Journal*, **2012**, 18, 143-52	5	186
243	Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. *Lancet Neurology, The*, **2010**, 9, 740-50	24.1	164
242	Guillain-Barr syndrome: a prospective, population-based incidence and outcome survey. *Neurology* , **2003**, 60, 1146-50	6.5	161
241	Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. *Neurology*, **2003**, 60, 634-9	6.5	160
240	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1005-15	5.5	157
239	Differential distribution and modulation of expression of alpha 1/beta 1 integrin on human endothelial cells. *Journal of Cell Biology*, **1991**, 114, 855-63	7.3	155
238	Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. *Archives of Neurology*, **2002**, 59, 1406-12		148
237	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. *Multiple Sclerosis Journal*, **2009**, 15, 779-88	5	141
236	Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. *Neurology*, **2004**, 62, 2031-7	6.5	141
235	In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. *Brain*, **2007**, 130, 2211-9	11.2	130

234	In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. *Brain*, **2001**, 124, 2540-9	11.2	129
233	Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 4923-8	5.6	114
232	Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. *Brain*, **2006**, 129, 2628-34	11.2	111
231	Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 1349-53	5.5	102
230	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 1802-9	5	99
229	Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. *NeuroImage*, **2005**, 24, 1139-46	7.9	99
228	Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. *Journal of Neurology, Neurosurgery and Psychiatry*, **2002**, 73, 148-53	5.5	98
227	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. *Multiple Sclerosis Journal*, **2012**, 18, 835-42	5	95
226	Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. *Immunopharmacology*, **2000**, 48, 95-100		90
225	Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. *Multiple Sclerosis Journal*, **2006**, 12, 47-57	5	86
224	Corpus callosum damage and cognitive dysfunction in benign MS. *Human Brain Mapping*, **2009**, 30, 2656-66	5.9	82
223	Cognitive impairment and structural brain damage in benign multiple sclerosis. *Neurology*, **2008**, 71, 1521-6	6.5	79
222	Predictive markers for response to interferon therapy in patients with multiple sclerosis. *Neurology*, **2008**, 70, 1119-27	6.5	78
221	Acknowledgement to Authors, Referees, and Readers. *Neurology and Therapy*, **2018**, 7, 395-396	4.6	78
220	Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. *Journal of Immunological Methods*, **2001**, 256, 141-52	2.5	77
219	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2010**, 16, 68-77	5	75
218	The proteoglycan chondroitin sulfate is present in a subpopulation of cultured astrocytes and in their precursors. *Developmental Biology*, **1987**, 123, 282-5	3.1	75
217	Chondroitin sulfate proteoglycan surrounds a subset of human and rat CNS neurons. *Journal of Neuroscience Research*, **1991**, 29, 225-34	4.4	74

216	Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 1141-3	5.5	69
215	Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. *Multiple Sclerosis Journal*, **2007**, 13, 490-501	5	69
214	Risk of cancer in patients with Guillain-Barr syndrome (GBS). A population-based study. *Journal of Neurology*, **2004**, 251, 321-6	5.5	69
213	Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. *European Cytokine Network*, **2001**, 12, 56-61	3.3	65
212	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. *Brain*, **2015**, 138, 3275-86	11.2	63
211	Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. *Journal of Immunological Methods*, **2007**, 321, 19-31	2.5	62
210	Immunohistochemical mapping of perineuronal nets containing chondroitin unsulfated proteoglycan in the rat central nervous system. *Cell and Tissue Research*, **1996**, 283, 283-95	4.2	60
209	Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. *PLoS ONE*, **2010**, 5, e8962	3.7	59
208	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. *Neurology*, **2011**, 77, 1887-95	6.5	59
207	Non-invasive ventilation in amyotrophic lateral sclerosis: a 10 year population based study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 377-81	5.5	59
206	Chondroitin 4-sulfate proteoglycan forms an extracellular network in human and rat central nervous system. *Journal of the Neurological Sciences*, **1990**, 100, 113-23	3.2	59
205	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. *Neurological Sciences*, **2009**, 30, 193-9	3.5	58
204	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. *Multiple Sclerosis Journal*, **2008**, 14, 1225-33	5	58
203	PML risk stratification using anti-JCV antibody index and L-selectin. *Multiple Sclerosis Journal*, **2016**, 22, 1048-60	5	57
202	Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. *Brain*, **2004**, 127, 259-68	11.2	57
201	Selective expression of the Met/HGF receptor in human central nervous system microglia. *Oncogene*, **1993**, 8, 219-22	9.2	56
200	A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis. *Archives of Neurology*, **2008**, 65, 1223-30		54
199	Immunogenicity of interferon beta: differences among products. *Journal of Neurology*, **2004**, 251 Suppl 2, II15-II24	5.5	53

198	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. *Multiple Sclerosis Journal*, **2010**, 16, 1360-6	5	52
197	Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. *Neurological Sciences*, **2005**, 26 Suppl 4, S183-6	3.5	52
196	Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). *Neurological Sciences*, **2007**, 28, 209-11	3.5	51
195	Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. *Journal of Neuroimmunology*, **2005**, 158, 195-203	3.5	51
194	Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). *Neurology*, **2003**, 61, S24-6	6.5	51
193	Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. *Neurology: Neuroimmunology and NeuroInflammation*, **2018**, 5, e498	9.1	50
192	Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. *Neurological Sciences*, **2007**, 28, 127-32	3.5	49
191	Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. *Neurology: Neuroimmunology and NeuroInflammation*, **2017**, 4, e317	9.1	48
190	Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. *Journal of Neurology, Neurosurgery and Psychiatry*, **2004**, 75, 1294-9	5.5	48
189	Extracellular matrix of cultured glial cells: selective expression of chondroitin 4-sulfate by type-2 astrocytes and their progenitors. *Experimental Cell Research*, **1990**, 187, 211-23	4.2	48
188	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. *Journal of Neurology*, **2007**, 254, 827-37	5.5	45
187	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. *Multiple Sclerosis Journal*, **2007**, 13, 1068-70	5	45
186	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. *Multiple Sclerosis Journal*, **2009**, 15, 620-6	5	44
185	Monoclonal antibodies to keratan sulfate immunolocalize ramified microglia in paraffin and cryostat sections of rat brain. *Journal of Histochemistry and Cytochemistry*, **1993**, 41, 481-7	3.4	42
184	Collagenase in the immunohistochemical demonstration of laminin, fibronectin and factor VIII/RAg in nervous tissue after fixation. *Histochemistry*, **1984**, 80, 157-63		42
183	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. *Brain*, **2017**, 140, 2814-2819	11.2	38
182	Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis. *Archives of Neurology*, **2011**, 68, 879-88		38
181	Immunohistochemical localization of chondroitin sulfate in normal and pathological human muscle. *Journal of the Neurological Sciences*, **1986**, 73, 233-44	3.2	38

180	Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers. *Neurology and Therapy*, **2015**, 4, 147-57	4.6	36
179	Presence and significant determinants of cognitive impairment in a large sample of patients with multiple sclerosis. *PLoS ONE*, **2013**, 8, e69820	3.7	36
178	Psychosocial issue in children and adolescents with multiple sclerosis. *Neurological Sciences*, **2010**, 31, 467-70	3.5	36
177	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. *Multiple Sclerosis Journal*, **2014**, 20, 577-87	5	35
176	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. *Multiple Sclerosis Journal*, **2013**, 19, 1508-17	5	35
175	Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson and Alzheimer Disease Patients. *Neurotoxicity Research*, **2016**, 30, 338-44	4.3	35
174	A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 26-30	5.5	34
173	High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. *European Journal of Endocrinology*, **2006**, 154, 745-51	6.5	34
172	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. *Neurological Sciences*, **2011**, 32, 1223-31	3.5	33
171	Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. *Neurology*, **2008**, 71, 1940-7	6.5	33
170	Cerebrospinal fluid findings in Devic neuromyelitis optica. *Neurological Sciences*, **2004**, 25 Suppl 4, S368-70	3.5	30
169	Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. *Journal of Neuroimmunology*, **2009**, 217, 74-9	3.5	29
168	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. *Neurological Sciences*, **2014**, 35, 307-16	3.5	28
167	Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. *Journal of NeuroImmune Pharmacology*, **2012**, 7, 665-72	6.9	28
166	A methodological reappraisal of non invasive high voltage electrical stimulation of lumbosacral nerve roots. *Clinical Neurophysiology*, **2011**, 122, 2071-80	4.3	28
165	Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. *Journal of Neurology*, **2018**, 265, 1850-1859	5.5	27
164	Prognostic indicators in pediatric clinically isolated syndrome. *Annals of Neurology*, **2017**, 81, 729-739	9.4	26
163	Cytokine profiles show heterogeneity of interferon- response in multiple sclerosis patients. *Neurology: Neuroimmunology and NeuroInflammation*, **2016**, 3, e202	9.1	26

162	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. *Neurology* , **2014**, 83, 1210-6	6.5	26
161	Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. *Archives of Neurology*, **2010**, 67, 402-7		26
160	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. *Multiple Sclerosis Journal*, **2006**, 12, 578-85	5	26
159	Three years of experience: the Italian registry and safety data update. *Neurological Sciences*, **2011**, 31 Suppl 3, 295-7	3.5	25
158	5D4 keratan sulfate epitope identifies a subset of ramified microglia in normal central nervous system parenchyma. *Journal of Neuroimmunology*, **1998**, 85, 69-77	3.5	25
157	Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. *Current Opinion in Neurology*, **2004**, 17, 241-6	7.1	25
156	The Effectiveness of a Body-Affective Mindfulness Intervention for Multiple Sclerosis Patients with Depressive Symptoms: A Randomized Controlled Clinical Trial. *Frontiers in Psychology*, **2017**, 8, 2083	3.4	24
155	Effects of isoxazolo-pyridinone 7e, a potent activator of the Nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mice. *PLoS ONE*, **2014**, 9, e108791	3.7	24
154	Laminin and fibronectin distribution in normal and pathological human muscle. *Journal of the Neurological Sciences*, **1983**, 60, 377-82	3.2	24
153	Glycosaminoglycan changes in human gliomas. A biochemical study. *Journal of Neuro-Oncology*, **1986**, 4, 43-8	4.8	23
152	Concomitant brain arterial and venous thrombosis in a COVID-19 patient. *European Journal of Neurology*, **2020**, 27, e38-e39	6	22
151	One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. *Journal of Neurology*, **2011**, 258, 895-903	5.5	22
150	Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse. *Neurological Sciences*, **2003**, 24, 130-3	3.5	22
149	No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. *European Journal of Neurology*, **2015**, 22, 585-7	6	21
148	In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. *Multiple Sclerosis Journal*, **2009**, 15, 789-94	5	21
147	Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. *Journal of Neuroimmunology*, **2007**, 192, 198-205	3.5	21
146	Transforming growth factor beta1 (TGFbeta1) mRNA level correlates with magnetic resonance imaging disease activity in multiple sclerosis patients. *Neuroscience Letters*, **1999**, 263, 21-4	3.3	21
145	High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. *Neurology and Therapy*, **2017**, 6, 145-152	4.6	20

144	Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. *Multiple Sclerosis Journal*, **2015**, 21, 1713-22	5	20
143	A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients. *Journal of Neuroimmunology*, **2016**, 292, 34-9	3.5	20
142	Prevalence and significant determinants of post-traumatic stress disorder in a large sample of patients with multiple sclerosis. *Journal of Clinical Psychology in Medical Settings*, **2013**, 20, 240-6	2	20
141	Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis. *PLoS ONE*, **2015**, 10, e0129291	3.7	20
140	Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis. *Journal of Neuroimmunology*, **2014**, 272, 99-102	3.5	20
139	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. *PLoS ONE*, **2016**, 11, e0153466	3.7	20
138	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. *Multiple Sclerosis Journal*, **2019**, 25, 399-407	5	20
137	Cerebrospinal fluid analysis and the determination of oligoclonal bands. *Neurological Sciences*, **2017** , 38, 217-224	3.5	19
136	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. *Neurological Sciences*, **2017**, 38, 1849-1858	3.5	19
135	Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. *Journal of Neuroinflammation*, **2015**, 12, 146	10.1	19
134	Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. *Multiple Sclerosis Journal*, **2009**, 15, 212-8	5	19
133	Acute-phase proteins investigation based on lectins affinity capture prior to 2-DE separation: application to serum from multiple sclerosis patients. *Electrophoresis*, **2010**, 31, 2882-93	3.6	19
132	Nurr1 reduction influences the onset of chronic EAE in mice. *Inflammation Research*, **2015**, 64, 841-4	7.2	18
131	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). *Multiple Sclerosis Journal*, **2016**, 22, 1163-73	5	18
130	Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. *PLoS ONE*, **2012**, 7, e38896	3.7	18
129	Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. *Journal of Immunological Methods*, **2008**, 336, 119-26	2.5	18
128	Glycosaminoglycans (GAGs) in human cerebral tumors. Part 1. Biochemical findings. *Acta Neuropathologica*, **1982**, 58, 115-9	14.3	18
127	The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice. *Cephalalgia*, **2016**, 36, 131-8	6.1	17

126	Interferon-beta responders and non-responders. A biological approach. *Neurological Sciences*, **2008**, 29 Suppl 2, S216-7	3.5	17
125	Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis. *Multiple Sclerosis Journal*, **2006**, 12, 738-46	5	17
124	Italian studies on early-onset multiple sclerosis: the present and the future. *Neurological Sciences*, **2004**, 25 Suppl 4, S346-9	3.5	17
123	Keratan sulphate is a marker of differentiation of ramified microglia. *Developmental Brain Research*, **1995**, 86, 233-41		17
122	Congenital muscular dystrophy associated with familial junctional epidermolysis bullosa letalis. *European Neurology*, **1993**, 33, 454-60	2.1	17
121	Glycosaminoglycans in human cerebral tumors. Part II. Histochemical findings and correlations. *Acta Neuropathologica*, **1982**, 57, 299-305	14.3	17
120	Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. *Frontiers in Immunology*, **2017**, 8, 321	8.4	16
119	Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients. *Journal of Immunological Methods*, **2002**, 262, 187-90	2.5	16
118	Biological monitoring of IFN-β therapy in Multiple Sclerosis. *Cytokine and Growth Factor Reviews*, **2015**, 26, 241-8	17.9	15
117	Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. *Journal of Neuroinflammation*, **2015**, 12, 132	10.1	15
116	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. *Neurological Sciences*, **2011**, 32, 351-8	3.5	15
115	Implications of neutralising antibodies on therapeutic efficacy. *Journal of the Neurological Sciences*, **2009**, 277 Suppl 1, S29-32	3.2	15
114	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. *Neurological Sciences*, **2005**, 26 Suppl 4, S200-3	3.5	15
113	A20 in Multiple Sclerosis and Parkinson's Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?. *Neurotoxicity Research*, **2017**, 32, 1-7	4.3	14
112	Evaluation of the impact of neutralizing antibodies on IFNβ response. *Clinica Chimica Acta*, **2015**, 449, 31-6	6.2	14
111	In vivo silencing of miR-125a-3p promotes myelin repair in models of white matter demyelination. *Glia*, **2020**, 68, 2001-2014	9	14
110	The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto's Thyroiditis. *Frontiers in Immunology*, **2018**, 9, 311	8.4	14
109	Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo study): rationale, design, and methodology. *Neurological Sciences*, **2013**, 34, 1297-307	3.5	14

108	Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients. *Clinical Immunology*, **2017**, 181, 83-88	9	14
107	The pharmacovigilance program on natalizumab in Italy: 2 years of experience. *Neurological Sciences*, **2009**, 30 Suppl 2, S163-5	3.5	14
106	Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. *Journal of Neurology*, **2004**, 251 Suppl 2, II31-9	5.5	14
105	Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial. *Trials*, **2012**, 13, 183	2.8	13
104	Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. *Journal of the Neurological Sciences*, **2005**, 237, 5-11	3.2	13
103	Immunohistochemical study of chondroitin sulfate in human gliomas. *Acta Neuropathologica*, **1986**, 72, 189-96	14.3	13
102	Comparison of Three PCR Assays for the Evaluation of Interferon-?? Biological Activity in Patients with Multiple Sclerosis. *Molecular Diagnosis and Therapy*, **2004**, 8, 185-194		13
101	Computerized posturography is more sensitive than clinical Romberg Test in detecting postural control impairment in minimally impaired Multiple Sclerosis patients. *Multiple Sclerosis and Related Disorders*, **2017**, 14, 51-55	4	12
100	Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). *Neurological Sciences*, **2017**, 38, 231-236	3.5	12
99	Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. *Frontiers in Neurology*, **2019**, 10, 253	4.1	12
98	Quality of life and patient preferences: identification of subgroups of multiple sclerosis patients. *Quality of Life Research*, **2015**, 24, 2173-82	3.7	12
97	Anti-inflammatory genes associated with multiple sclerosis: a gene expression study. *Journal of Neuroimmunology*, **2015**, 279, 75-8	3.5	12
96	Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy Adherence, Hospital Reliability Perception, and Services Provided Quality. *Multiple Sclerosis International*, **2014**, 2014, 752318	1.1	12
95	Morphological and biochemical investigations of mitral valve endocardiosis in pigs. *Research in Veterinary Science*, **1997**, 62, 121-5	2.5	12
94	Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis?. *Acta Neurologica Scandinavica*, **2004**, 109, 61-5	3.8	12
93	The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial. *BMC Neurology*, **2016**, 16, 7	3.1	12
92	NURR1 deficiency is associated to ADHD-like phenotypes in mice. *Translational Psychiatry*, **2019**, 9, 207	8.6	11
91	Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. *Neurology*, **2021**,	6.5	11

90	Immunomodulatory Effect of Pregnancy on Leukocyte Populations in Patients With Multiple Sclerosis: A Comparison of Peripheral Blood and Decidual Placental Tissue. *Frontiers in Immunology*, **2019**, 10, 1935	8.4	10
89	The role of fatigue in the associations between exercise and psychological health in Multiple Sclerosis: Direct and indirect effects. *Mental Health and Physical Activity*, **2013**, 6, 87-94	5	10
88	Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. *Neurological Sciences*, **2008**, 29, 185-7	3.5	10
87	Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b. *Multiple Sclerosis Journal*, **2003**, 9, 420-3	5	10
86	Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. *Neurological Sciences*, **2005**, 26 Suppl 4, S213-4	3.5	10
85	Quantitative PCR reveals increased levels of tumor necrosis factor-alpha mRNA in peripheral blood mononuclear cells of multiple sclerosis patients during relapses. *Journal of Interferon and Cytokine Research*, **1999**, 19, 575-81	3.5	10
84	Cellulose acetate electrophoresis of glycosaminoglycans in the central nervous system. *Electrophoresis*, **1984**, 5, 97-101	3.6	10
83	Acute muscle necrosis after chronic overdosage of phenformin and fenfluramine. *Muscle and Nerve*, **1978**, 1, 245-7	3.4	10
82	Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. *Therapeutic Drug Monitoring*, **2017**, 39, 339-343	3.2	9
81	Italian national guidelines for the screening of gestational diabetes: Time for a critical appraisal?. *Nutrition, Metabolism and Cardiovascular Diseases*, **2017**, 27, 717-722	4.5	9
80	NURR1 Impairment in Multiple Sclerosis. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	9
79	A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart®: the FUTURE study. *Neurological Sciences*, **2017**, 38, 1999-2005	3.5	9
78	Disappearance of the Vicia villosa-positivity from the perineuronal net containing chondroitin proteoglycan after chondroitinase digestion. *Brain Research*, **1995**, 673, 344-8	3.7	9
77	Chondroitin, chondroitin 6-sulphate, chondroitin 4-sulphate and dermatan sulphate proteoglycans in normal and pathological human muscle. *Journal of the Neurological Sciences*, **1987**, 81, 247-59	3.2	9
76	Italian consensus on treatment of spasticity in multiple sclerosis. *European Journal of Neurology*, **2020**, 27, 445-453	6	9
75	Anal sphincter dysfunction in multiple sclerosis: an observation manometric study. *Open Medicine (Poland)*, **2016**, 11, 509-517	2.2	9
74	The heritage of glatiramer acetate and its use in multiple sclerosis. *Multiple Sclerosis and Demyelinating Disorders*, **2016**, 1,	0	8
73	Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation. *Neurological Sciences*, **2012**, 33, 863-7	3.5	8

72	Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. *Neurological Sciences*, **2008**, 29 Suppl 2, S227-9	3.5	8
71	Biochemical and histochemical evaluation of glycosaminoglycans in brain tumors induced in rats by nitrosourea derivatives. *Journal of Neuro-Oncology*, **1983**, 1, 299-306	4.8	8
70	On the nature of the so-called monstrocellular sarcoma of the brain. *Neurosurgery*, **1980**, 6, 391-7	3.2	8
69	Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual Subjects. *PLoS ONE*, **2016**, 11, e0155268	3.7	8
68	Decline of Neuropsychological Abilities in a Large Sample of Patients with Multiple Sclerosis: A Two-Year Longitudinal Study. *Frontiers in Human Neuroscience*, **2016**, 10, 282	3.3	8
67	Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. *Therapeutic Drug Monitoring*, **2017**, 39, 308-315	3.2	7
66	Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents. *Therapeutic Drug Monitoring*, **2017**, 39, 350-355	3.2	7
65	Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients. *Journal of Immunological Methods*, **2017**, 445, 53-58	2.5	7
64	Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients. *Neurology and Therapy*, **2020**, 9, 197-203	4.6	7
63	Glutamate dehydrogenase (GDH) deficiency in different types of progressive hereditary cerebellar ataxia. *Acta Neurologica Scandinavica*, **1988**, 78, 394-400	3.8	7
62	Ineffectiveness of allopurinol in Duchenne muscular dystrophy. *Muscle and Nerve*, **1981**, 4, 176-8	3.4	7
61	Clinical Aspects of Immunogenicity to Biopharmaceuticals **2008**, 27-56		7
60	Acute confusional state in HaNDL syndrome (transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis). *Neurological Sciences*, **2015**, 36, 477-8	3.5	6
59	Prevalence of Posttraumatic Stress Disorder in Patients With Multiple Sclerosis. *Journal of Nervous and Mental Disease*, **2018**, 206, 149-151	1.8	6
58	A Comprehensive Review on Copemyl. *Neurology and Therapy*, **2017**, 6, 161-173	4.6	6
57	Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*, **2007**, 69, 1552; author reply 1553	6.5	6
56	Mitochondrial abnormalities of late motor neuron degeneration following poliomyelitis and other neurogenic muscular atrophies. *Journal of Neurology*, **1979**, 221, 193-201	5.5	6
55	Epidemiology of Duchenne muscular dystrophy in the province of Turin. *Italian Journal of Neurological Sciences*, **1981**, 2, 81-4		6

54	Histochemical and ultrastructural findings in a case of centronuclear myopathy. *European Neurology* , **1978**, 17, 327-32	2.1	6
53	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. *Multiple Sclerosis Journal*, **2019**, 25, 856-866	5	5
52	CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept study. *Journal of Neuroimmunology*, **2014**, 277, 127-33	3.5	5
51	A new neurophysiological approach to assess central motor conduction damage to proximal and distal muscles of lower limbs. *Clinical Neurophysiology*, **2014**, 125, 133-41	4.3	5
50	Motor neuron disease following poliomyelitis. Bioptic study of five cases. *European Neurology*, **1980** , 19, 414-8	2.1	5
49	Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod. *European Journal of Neurology*, **2019**, 26, 667-672	6	5
48	Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-Therapy. *Neurology and Therapy*, **2015**, 4, 53-60	4.6	4
47	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. *Neurology and Therapy*, **2020**, 9, 443-457	4.6	4
46	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. *Neurological Sciences*, **2020**, 41, 2843-2851	3.5	4
45	Quantitation of nanogram amounts of glycosaminoglycans in samples containing proteins by a new densitometric method. *Electrophoresis*, **1985**, 6, 35-38	3.6	4
44	Sporadic oculopharyngeal myopathy with abnormal mitochondria. *Acta Neurologica Belgica*, **1978**, 78, 373-82	1.5	4
43	Osteomalacic myopathy in a case of diffuse nodular lipomatosis of the small bowel. *Acta Neurologica Belgica*, **1982**, 82, 65-71	1.5	4
42	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. *JAMA Neurology*, **2021**, 78, 726-735	17.2	4
41	The transcription factor Nurr1 is upregulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice. *DMM Disease Models and Mechanisms*, **2020**, 13,	4.1	4
40	Overexpression of the ubiquitin-editing enzyme A20 in the brain lesions of Multiple Sclerosis patients: moving from systemic to central nervous system inflammation. *Brain Pathology*, **2021**, 31, 283-296	6	4
39	Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. *European Journal of Neurology*, **2021**, 28, 567-578	6	4
38	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. *Frontiers in Neurology*, **2019**, 10, 695	4.1	3
37	The still under-investigated role of cognitive deficits in PML diagnosis. *Multiple Sclerosis and Demyelinating Disorders*, **2017**, 2,	0	3

36	Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning. *Multiple Sclerosis Journal*, **2014**, 20, 889-91	5	3
35	Progressive multifocal leukoencephalopathy in Good syndrome. *International Journal of Infectious Diseases*, **2010**, 14 Suppl 3, e367-8	10.5	3
34	On the Nature of the So-Called Monstrocellular Sarcoma of the Brain. *Neurosurgery*, **1980**, 6, 391-397	3.2	3
33	Myoglobinuria: presentation of personal cases and review of the literature. *Italian Journal of Neurological Sciences*, **1981**, 2, 275-82		3
32	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. *Journal of Neurology*, **2021**, 1	5.5	3
31	Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment. *Multiple Sclerosis and Related Disorders*, **2020**, 46, 102592	4	2
30	Classification of individuals based on ex-vivo glatiramer acetate-induced interferon- and interleukin-4 response. *Multiple Sclerosis Journal*, **2012**, 18, 1484-92	5	2
29	Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. *Molecular Diagnosis and Therapy*, **2004**, 8, 185-94		2
28	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2020**, 6, 2055217320972137	2	2
27	Assessing measurement invariance of MSQOL-54 across Italian and English versions. *Quality of Life Research*, **2020**, 29, 783-791	3.7	2
26	Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study. *Multiple Sclerosis and Demyelinating Disorders*, **2016**, 1,	0	2
25	Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. *Multiple Sclerosis and Related Disorders*, **2021**, 54, 103090	4	2
24	Analysis of the Gadolinium retention in the Experimental Autoimmune Encephalomyelitis (EAE) murine model of Multiple Sclerosis. *Journal of Trace Elements in Medicine and Biology*, **2021**, 68, 126831	4.1	2
23	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. *Journal of International Medical Research*, **2008**, 36, 204-8; author reply 208-10	1.4	2
22	TNFAIP3 Deficiency Affects Monocytes, Monocytes-Derived Cells and Microglia in Mice. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	1
21	Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. *Neurological Sciences*, **2016**, 37, 2019-2023	3.5	1
20	Access to social security benefits among multiple sclerosis patients in Italy: A cross-sectional study. *Multiple Sclerosis and Related Disorders*, **2018**, 24, 107-112	4	1
19	The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. *Global & Regional Health Technology Assessment*, **2019**, 2019, 228424031983852	0.2	1

18	Two-dimensional immunoelectrophoresis of unconcentrated cerebrospinal fluid. *Journal of the Neurological Sciences*, **1978**, 37, 199-203	3.2	1
17	Biochemical, histochemical and immunohistochemical study of glycosaminoglycans in human meningiomas. *Basic and Applied Histochemistry*, **1989**, 33, 239-49		1
16	Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report. *Neurological Sciences*, **2021**, 42, 25-28	3.5	1
15	Exposure to fine particulate matter (PM) hampers myelin repair in a mouse model of white matter demyelination. *Neurochemistry International*, **2021**, 145, 104991	4.4	1
14	Coverage of the requirements of first and second level stroke unit in Italy. *Neurological Sciences*, **2021**, 42, 1073-1079	3.5	1
13	Validation of an Algorithm to Detect Multiple Sclerosis Cases in Administrative Health Databases in Piedmont (Italy): An Application to the Estimate of Prevalence by Age and Urbanization Level. *Neuroepidemiology*, **2021**, 55, 119-125	5.4	1
12	Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.. *Frontiers in Immunology*, **2021**, 12, 775151	8.4	0
11	The reliability of objective fatigue measures in Multiple Sclerosis Patients. *Biomedical Signal Processing and Control*, **2020**, 56, 101696	4.9	0
10	Successful pregnancy and disease outcomes in a NMOSD patient treated with tocilizumab. *Neuroimmunology Reports*, **2021**, 1, 100014		0
9	The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of NR4A Genes in Microglia Cell Line. *Current Issues in Molecular Biology*, **2022**, 44, 1247-1256	2.9	0
8	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. *Neurology*, **2022**, 98, e1626-e1636	6.5	0
7	Neurology and Therapy: Looking Back on 2018 and Forward to 2019. *Neurology and Therapy*, **2019**, 8, 1-3	4.6	
6	Acknowledgement to Authors, Referees and Readers 2019. *Neurology and Therapy*, **2019**, 8, 513-515	4.6	
5	Detection of Neutralizing Antibodies against Interferon Beta by Real-Time RT-PCR **2011**, 157-174		
4	Induction of brain tumors by transplagental enu: Correlation between neurocytogenesis and tumor development. *International Journal of Developmental Neuroscience*, **1985**, 3, 431-431	2.7	
3	AuthorsQResponse to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl. *Neurology and Therapy*, **2018**, 7, 391-393	4.6	
2	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. *Health and Quality of Life Outcomes*, **2021**, 19, 224	3	
1	The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes.. *Molecular Biology Reports*, **2022**, 1	2.8	